Clinical Study for Cell-cultured Influenza Vaccine
Phase 4
- Conditions
- Influenza A(H7N9)Influenza A(H7N9), Vaccine
- Registration Number
- JPRN-jRCTs031200112
- Lead Sponsor
- Sato Morihiko
- Brief Summary
The national stockpiled cell culture-derived H7N9 influenza vaccine (IDCDC-RG56N strain) was found to be sufficiently immunogenic, with higher adverse reactions after the second dose compared to the first, but no major safety concerns. The vaccine strain and the original wild strain were found to be sufficiently immunogenic. Cross-immunity to the wild-type Anhui strain was observed, but not to the vaccine strain derived from A/Gansu/23277/2019-like.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Healthy Volunteers
Exclusion Criteria
History of influenza A(H7) infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody titer
- Secondary Outcome Measures
Name Time Method Side Effect and Adverse Reaction